Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 202 ...
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of ...
Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, ...
Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein occlusion, according to a speaker at Retina 2026.In light of faricimab’s ...
Please provide your email address to receive an email when new articles are posted on . This activity is supported by independent medical education grants from 4D Molecular Therapeutics; AbbVie Inc.; ...
In his decades-long career in tech journalism, Dennis has written about nearly every type of hardware and software. He was a founding editor of Ziff Davis’ Computer Select in the 1990s, senior ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Zoe Vanderweide Zoe Vanderweide is a writer focused on style and accessories.
Noom is a personalized health and wellness app that provides access to coaching in your pocket. The company’s habit-changing solutions include daily lessons and progress tracking for weight loss and ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Abigail Bailey Abigail Bailey is a writer on the kitchen team. Her subjects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results